Best Healthcare Technology Stocks To Buy For 2014

SAN FRANCISCO — A federal jury on Thursday returned its damages verdict against Samsung, saying the electronics giant should pay Apple $290 million in the patent dispute involving technology used in iPhones and iPads.

The juror decision came after several days of deliberations that began on Tuesday after U.S. District Judge Lucy Koh gave juror instructions following closing arguments from both sides in the San Jose courtroom.

Apple and Samsung are embroiled in worldwide patent litigation disputes spanning multiple courts. Legal experts say Apple’s suits against Samsung serve as a proxy war against Google’s Android operating system.

Apple was seeking $380 million while Samsung had said it should only pay $52 million for the use of such features as the iPhone maker’s “pinch to zoom” in 13 older products.

Best Healthcare Technology Stocks To Buy For 2014: SPDR EURO STOXX 50 ETF (FEZ)

SPDR DJ Euro Stoxx 50 ETF (the Fund), formerly DJ Euro Stoxx 50 ETF, seeks to replicate as closely as possible the price and yield of the Dow Jones EURO STOXX 50 Index (the Index). The Index seeks to provide a blue-chip representation of the market sector leaders in the Eurozone. The Index represents the performance of the 50 largest companies within the Eurozone portion of the Dow Jones STOXX Total Market Index. The Index is a free-float market capitalization weighted index that captures approximately 60% of the underlying market and covers approximately 95% of the free-float market capitalization of the investable universe in the Eurozone.

The Fund utilizes a passive or indexing approach to invest in a portfolio of stocks to replicate the Index. The Fund’s investment advisor is SSgA Funds Management, Inc.

Advisors’ Opinion:

  • [By Chris Ciovacco]

    In Thursday’s ETF analysis, evidence is presented that supports increasing demand for assets that get a tailwind from a weak U.S. dollar, including emerging markets (EEM) and foreign stocks (EFA). Casting a wider economic net, our market model told us to start buying stocks last week even with the threat of a U.S. default. Wednesday, we continued with our incremental allocation shifts by adding some exposure to the energy sector. Thursday, we sat tight holding long positions in small caps (IJR), Europe (FEZ), emerging markets and technology (QQQ). The upper bounds of the bullish S&P 500 trend channel shown below may offer some resistance to the market’s near vertical ascent.

  • [By Tom Aspray]

    The news out of the Eurozone continues to improve as their Purchasing Managers Index rose to 51.7 in August consistent with an expanding economy. The chart shows a nice trend here suggesting that the worst by indeed be over. A deeper pullback in some of the euro ETFs like SPDR Euro STOXX 50 ETF (FEZ) should create a buying opportunity.

Best Healthcare Technology Stocks To Buy For 2014: Reed Elsevier PLC(RUK)

Reed Elsevier PLC provides professional information solutions worldwide. The company?s Elsevier segment offers scientific, technical, and medical information solutions. This segment publishes science and technology research articles and book titles; and abstract and citation database of research literature, as well as offers information and workflow tools that help researchers generate insights in the advancement of scientific discovery. The Elsevier segment also provides medical journals, books, reference works, databases, and online information tools to medical researchers, doctors, nurses, allied health professionals, students, hospitals, research institutions, health insurers, managed healthcare organizations, and pharmaceutical companies. Its LexisNexis Risk Solutions segment offers data and analytics for the insurance industry; risk management, identity verification, fraud detection, credit risk management, and compliance solutions for financial institutions; invest igative solutions; and employment-related, resident and volunteer screening services. The company?s Lexisnexis Legal and Professional segment provides legal, tax, regulatory, and business information solutions. Its Reed Exhibitions segment organizes exhibitions and conferences for the broadcasting, TV, music, and entertainment; building and construction; electronics and electrical engineering; alternative energy, oil, and gas; engineering, manufacturing, and processing; gifts; interior design; IT and telecoms; jewelry; life sciences and pharmaceuticals; marketing; property and real estate; sports and recreation; and travel sectors. The company?s Reed Business Information segment provides data services, information, and marketing solutions to business professionals; produces industry critical data services, lead generation tools, and online community and job sites; and publishes business magazines. Reed Elsevier PLC was founded in 1894 and is based in London, the United Kin g dom.

Advisors’ Opinion:

  • [By Zarr Pacificador]

    A look at Reed Elsevier
    Today, I’m evaluating Reed Elsevier  (LSE: REL  ) (NYSE: RUK  ) , a professional information solutions provider, which currently trades at 743 pence. Here are my thoughts:

  • [By David O’Hara]

    2. Reed Elsevier 
    Reed Elsevier  (LSE: REL  ) (NYSE: RUK  ) is a provider of “professional information solutions.” Products include leading industry journals — Reed Elsevier is publisher of both The Lancet and Gray’s Anatomy.

  • [By Rupert Hargreaves]

    Today I am looking at Reed Elsevier  (LSE: REL  ) (NYSE: RUK  ) to determine whether you should consider buying the shares at 734 pence.

Best Healthcare Technology Stocks To Buy For 2014: Zions Bancorporation(ZION)

Zions Bancorporation, a multi bank holding company, provides various banking and related products and services in the United States. The company offers community banking services, including small and medium-sized business and corporate banking; commercial and residential development, construction, and term lending; retail banking; treasury cash management and related products and services; residential mortgage; trust and wealth management; and investment activities. It also provides personal banking services to individuals, including home mortgages, bankcard, installment loans, home equity lines of credit, checking accounts, savings accounts, time certificates, safe deposit facilities, direct deposits, and automated teller machine access. In addition, the company offers small business administration lending services; secondary market agricultural real estate mortgage loans; municipal finance advisory and underwriting services; and wealth management and online brokerage ser vices. As of December 31, 2010, Zions Bancorporation offered its banking services through 495 branches in Utah, California, Texas, Arizona, Nevada, Colorado, Idaho, Washington, Oregon, and New Mexico. The company was founded in 1873 and is headquartered in Salt Lake City, Utah.

Advisors’ Opinion:

  • [By Ben Levisohn]

    Each month, Credit Suisse’s small-cap strategists ask the firm’s analyst to name their favorite small- and mid-cap stocks. This month, six new stocks made the list: RPM International (RPM), SunCoke Energy (SXC), Zions Bancorp (ZION), Signature Bank (SBNY), Edwards Lifesciences (EW) and Rexnord (RXN).

  • [By Jon C. Ogg]

    Citi and four other banks – Zions Bancorp (NASDAQ: ZION), Banco Santander (NYSE: SAN), HSBC Holdings PLC (NYSE: HSBC) for its North American operations, Royal Bank of Scotland PLC (NYSE: RBS) – will have to resubmit their plans with the Fed, and then they must get approval in writing from the Fed to increase buybacks and dividends. The foreign banks that failed will be restricted from paying higher dividends back to their parent companies.

  • [By Jim Jubak]

    Last Thursday’s Round One looked at 30 big US banks to see which met the Fed’s capital targets in the event of a US financial and economic crisis. Only Zions Bancorp (ZION) rallied to meet the Fed’s target. In the event of a crisis, Zion’s capital ratio would fall to 3.5%. That’s below the 5% minimum set by the Fed.

  • [By Ben Levisohn]

    What a difference a day makes. After plunging yesterday, stocks gained today as investors came to terms with the Federal Reserve’s revised schedule for higher rates, sending shares of Invesco (IVZ), Zions Bancorporation (ZION), JPMorgan Chase (JPM) and Charles Schwab (SCHW) soaring.

Best Healthcare Technology Stocks To Buy For 2014: Australian Dollar(AU)

AngloGold Ashanti Limited primarily engages in the exploration and production of gold. It also produces silver, uranium oxide, and sulfuric acid. The company conducts gold-mining operations in South Africa; continental Africa, including Ghana, Guinea, Mali, Namibia, and Tanzania; Australia; and the Americas, which include Argentina, Brazil, and the United States. It also has mining or exploration operations in the Democratic Republic of the Congo, Guinea, and Colombia. As of December 31, 2010, the company had proved and probable gold reserves of 71.2 million ounces. The company has a strategic alliance with Thani Dubai Mining Limited to explore, develop, and operate mines across the Middle East and parts of North Africa. AngloGold Ashanti Limited, formerly known as Vaal Reefs Exploration and Mining Company Limited, was founded in 1944 and is headquartered in Johannesburg, South Africa.

Advisors’ Opinion:

  • [By Jim Powell]

    In addition to holding Goldcorp and Barrick Gold, the fund tracks the performance of Newmont Mining (NEM), Newcrest Mining (NCMGY), AngloGold Ashanti (AU), and several other industry leaders.

  • [By Patricio Kehoe] stion arises: Why is First Eagle bullish regarding such a company? The answer might lie in the huge discount at which the third-largest gold producer by output is trading, along with a certain degree of long-term optimism.

    Huge Holdings Point to Long-Term Commitment

    Since First Eagle recently increased its stake in Anglogold by more than 20%, bringing his total holding to over 32.5 million shares, I believe we are looking at a long-term investment. I am keen on pointing this out, since the stock is currently performing very poorly, and has already lost around 275% of its value year to date. Above average production costs and plummeting gold prices have put a huge deal of pressure on the gold miner, leading to very poor results. In addition, since many of its operations are in geopolitically risky countries such as Mali and the Democratic Republic of Congo, shareholders have been shedding this stock in large volumes.

    Although Anglogold had a very rough year, and will continue to face elevated cash costs and reduced margins going into 2014, there are some positive signals looking forward. One of the most promising features, are the firm’s operations in South America and Australia, which are enjoying solid organic growth. Although investors will have to wait some years for assets in these regions to reach full production, large profits should be achieved in the long-term. In other words, First Eagle surely has its eyes set on the company’s new projects, and their future growth potential.

    Projected Growth and Low Price

    Another attractive feature investors must keep in mind is a stock’s growth potential. When looking at Anglogold, this becomes especially relevant, as a comparison to Barrick Gold Corp (ABX) will demonstrate. Anglogold currently offers 13.6% returns on invested capital, compared to Barrick’s -2.8%, and has an EBITDA growth rate of 465.7%, the highest in the industry. Thus, whereas the Canadian mine r has a negative EPS

Best Healthcare Technology Stocks To Buy For 2014: NPS Pharmaceuticals Inc.(NPSP)

NPS Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic products for gastrointestinal and endocrine disorders, and various medical needs. The company?s primary clinical programs include two therapeutic peptides to restore or replace biological functions comprising GATTEX, a Phase 3 clinical trial product for short bowel syndrome; and Natpara, a recombinant human parathyroid hormone 1-84, which is in Phase 3 clinical development trials. It also develops NPSP790 and NPSP795 calcilytic compounds that are in Phase I trials for the treatment of rare endocrine disorders. The company has collaborative and license agreements with Amgen Inc., Janssen, GlaxoSmithKline, Kyowa Hakko Kirin, and Nycomed Danmark ApS. NPS Pharmaceuticals, Inc. was founded in 1986 and is based in Bedminster, New Jersey.

Advisors’ Opinion:

  • [By Louis Navellier]

    SVA is a strong buy at the current price.

    Biotech Stocks to Buy: NPS Pharmaceuticals (NPSP)

    NPS Pharmacuticals (NPSP) currently has five drugs  for things like osteoporosis, hyperparathyroidism, pain management and short bowel syndrome. They focus their research efforts right now on things like gastrointestinal, psychiatric, neurological and  bone and mineral disorders. The company had triple digit gains in sales and earnings in the most recent quarter and the strong fundamentals were noticed by Portfolio Grader.

  • [By Jesse Solomon]

    NPS Pharmaceuticals (NPSP), for example, created a drug for treating short bowel syndrome. And Hyperion Therapeutics (HPTX) is developing a drug for hepatic encephalopathy, a decline of brain function that according to the National Institute of Health occurs when the liver is no longer able to remove toxins from the blood. Those stocks are up 20% and 40%, respectively, this year.

  • [By George Budwell]

    NPS Pharmaceuticals (NASDAQ: NPSP  ) continued its torrid ascent  jumping another 10% last week. NPS shares have now risen 225% year to date, propelled primarily by the commercial launch of the company’s orphan drug for short bowel syndrome, or SBS, called Gattex. Gattex was approved by the FDA in 2012 and launched last February.

  • [By Jon C. Ogg]

    NPS Pharmaceuticals Inc. (NASDAQ: NPSP) is among the best revenue growth possibilities for biotech in 2014. The company’s revenue growth is expected to be 71%. We would caution that the consensus analyst price target of $37 implies more than 40% upside, but what our readers need to know is that this stock has been an incredibly volatile one. With shares around $25, it has a 52-week range of $7.35 to $35.72.

Best Healthcare Technology Stocks To Buy For 2014: First Advantage Bancorp(FABK)

First Advantage Bancorp operates as the holding company for First Federal Savings Bank that provides various financial services to individuals and businesses in Tennessee. The company offers various deposit products comprising non-interest-bearing demand deposits, such as checking accounts; interest-bearing demand accounts, including NOW and money market accounts; regular savings accounts; and certificates of deposit. Its loan portfolio include real estate mortgage loans, including one-to-four family residential loans and nonresidential real estate loans; construction loans for one-to-four family homes, commercial, multi-family, and other nonresidential purposes; land loans for developing vacant land; consumer loans consisting primarily of home equity loans; and commercial business loans secured by equipment, inventory, or accounts receivable to small businesses. As of June 10, 2010, the company operated five full-service offices in Montgomery County. First Advantage Banco rp was founded in 1953 and is headquartered in Clarksville, Tennessee.

Advisors’ Opinion:

  • [By Tim Melvin]

    PL Capital has not filed any 13Ds in a couple of months, but earlier this year it disclosed a 5.99% position in shares of First Advantage Bancorp (FABK). The Clarksville, Tenn.-based bank has seven branches and trades at about 75% of book value. PL Capital also filed a 13D announcing 8% ownership of Mutual First Financial (MFSF) over the summer. The bank has 31 branches and is based in Muncie, Ind. — an area that has seen substantial consolidation in the past few years.

Best Healthcare Technology Stocks To Buy For 2014: Fresenius Medical Care Corporation (FMS)

Fresenius Medical Care AG & Co. KGaA, a dialysis company, provides products and services for patients with chronic kidney diseases. As of May 12, 2011, it provided dialysis care services to 216,942 patients through its network of 2,769 dialysis clinics primarily in North America, Europe, Latin America, the Asia-Pacific, and Africa. The company also develops and manufactures various dialysis products, including hemodialysis machines, dialyzers, hemofilters, dialysis fluid filters, tubing systems, fistula needles, dialysis related equipment, acute hemodialysis machines, plasma filters, acute tubing systems and cassettes, catheters, and related disposable products for chronic hemodialysis, acute therapy, home therapy, and therapeutic apheresis, as well as dialysis drugs. In addition, it provides laboratory services. Fresenius Medical sells its products through distributors. The company was founded in 1996 and is headquartered in Bad Homburg, Germany.

Advisors’ Opinion:

  • [By Louie Grint]

    Still unaffected
    First, Fresenius Medical Care (NYSE: FMS  ) is the No. 1 global provider of dialysis equipment. It enjoys leading market share of almost 33% in its home country.

  • [By John Udovich]

    Small cap dialysis stock Rockwell Medical Inc (NASDAQ: RMTI) looks set to decline when the market opens after Brean Capital initiated coverage with a sell rating and a price target of $4.00, meaning it might be time to take a closer look at what is going on with the stock along with the performance of large cap dialysis stocks DaVita Healthcare Partners (NYSE: DVA) and Fresenius Medical Care (NYSE: FMS) along with small cap dialysis stocks NxStage Medical, Inc (NASDAQ: NXTM). 

Best Healthcare Technology Stocks To Buy For 2014: Invesco Mortgage Capital Inc (IVR)

Invesco Mortgage Capital Inc., incorporated in June 2008, is a real estate investment trust (REIT). The Company is primarily focused on investing in, financing and managing residential and commercial mortgage-backed securities and mortgage loans, which it collectively refers to as its target assets. The Company’s target assets consist of residential mortgage-backed securities (RMBS) for which the United States Government agency, such as the Government National Mortgage Association (Ginnie Mae) or a federally chartered corporation, such as the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac) guarantees payments of principal and interest on the securities. It refers to these securities as Agency RMBS. Its Agency RMBS investments include mortgage pass-through securities and may include collateralized mortgage obligations (CMOs). It also invests in RMBS that are not issued or guaranteed by the United States Govern ment agency (non-Agency RMBS), commercial mortgage-backed securities (CMBS) and residential and commercial mortgage loans.

The Company finances its Agency RMBS, non-Agency RMBS and CMBS investments through short-term borrowings structured as repurchase agreements. The Company’s manager is Invesco Advisors Inc. The Company also finances its investments in certain non-Agency RMBS, CMBS and residential and commercial mortgage loans by contributing capital to the Invesco Mortgage Recovery Feeder Fund (Invesco IMRF Fund) that invests in public-private investment funds (PPIF) managed by the Company’s manager. The Company’s manager is a wholly owned subsidiary of Invesco Ltd.

Advisors’ Opinion:

  • [By Amanda Alix]

    All mREITs are taking it on the chin
    The agency crew, led by heavy hitters Annaly Capital (NYSE: NLY  ) , American Capital Agency (NASDAQ: AGNC  ) , and Armour Residential (NYSE: ARR  ) , have all been close to hitting 52-week lows, but the blood-letting hasn’t stopped there. Even hybrid mortgage REITs, which also buy some non-agency paper, have plunged, as well. Two Harbors (NYSE: TWO  ) , which enjoyed such a nice lift post-earnings about a month ago, recently sunk to new lows, and Invesco Mortgage Capital (NYSE: IVR  ) has also slipped, even after its CIO’s recent show of faith, making a sizable insider purchase of stock less than two weeks ago.

  • [By Amanda Alix]

    Analysts at odds over mREITs
    Financial analysts have been busy noting the underperformance of mREITs lately, especially since the Fed dropped the QE3 taper bombshell almost two weeks ago — immediately igniting fears of rising interest rates, which would decrease the value of the trusts’ legacy assets, thus dinging book values. The pain hasn’t been limited to the stocks mentioned above,  as CYS Investments (NYSE: CYS  ) , and even hybrids like Invesco (NYSE: IVR  ) , have been on a roller-coaster ride ever since.

  • [By Sean Williams]

    In contrast, non-agency mREITs often have to be more careful with their leverage since loan defaults actively impact their bottom-line profit, and rapidly rising interest rates, such as what we saw over the past few weeks, can trigger MBS and other security sales at a loss. In return for more risk, non-agency securities pay out higher yields. Take, for example, Invesco Mortgage Capital (NYSE: IVR  ) , a buyer of agency and non-agency RMBSes, which delivered what might seem like an uninspiring 1.64% net interest margin in the first quarter with a leverage ratio of 6.4. Now compare that to agency-only mREIT Annaly Capital, whose net interest margin fell 80 basis points from the year-ago period in the first quarter to just 0.91%, but with a higher leverage ratio of 6.6.

  • [By Monica Wolfe]

    Invesco Mortgage Capital (IVR)

    President and CEO of Invesco Richard King reported a rather notable insider buy on Aug. 5. The CEO purchased 6,500 shares of company stock at an average price of $15.41 per share. This purchase cost King a total of $100,165. Since this buy, the share price has increased a minor 0.13%. King now holds on to at least 56,545 shares of Invesco Mortgage stock.

Best Healthcare Technology Stocks To Buy For 2014: Glatfelter (GLT)

P. H. Glatfelter Company manufactures and sells specialty papers and fiber-based engineered materials in the United States and internationally. It offers carbonless and forms papers for credit card receipts, multi-part forms, security papers, and other end-user applications; book publishing papers for the production of hardbound books and other book publishing needs; envelope and converting papers for the direct mail market, shopping bags, and other converting applications; and engineered products for digital imaging, transfer, casting, release, postal, playing card, and other niche specialty applications. The company also provides food and beverage paper used for tea bags and single serve coffee products; metallized products used in the labeling of beer bottles, innerliners, gift wrap, self-adhesive labels, and other consumer products applications; and composite laminates papers used in production of decorative laminates, furniture, and flooring applications, as well as a line of paper products used in batteries, medical masks, and other engineered applications. In addition, it offers airlaid non-woven fabric-like materials used in feminine hygiene products, adult incontinence products, cleaning pads and wipes, food pads, napkins and tablecloths, and baby wipes. The company markets its products directly, as well as through wholesale paper merchants, brokers, and agents. P. H. Glatfelter Company was founded in 1864 and is headquartered in York, Pennsylvania.

Advisors’ Opinion:

  • [By Marc Bastow]

    Specialty papers and and fiber-based materials manufacturer P.H. Glatfelter (GLT) raised its quarterly dividend 10% to 11 cents per share, payable May 1 to shareholders of record as of April 3.
    GLT Dividend Yield: 1.44%

  • [By Eric Volkman]

    Glatfelter (NYSE: GLT  ) has a new asset in its portfolio. The company announced it has finalized the acquisition of Germany-based Dresden Papier, which according to the American firm is “the leading global supplier of nonwoven wallpaper base materials.”

Best Healthcare Technology Stocks To Buy For 2014: NYSE Euronext Inc.(NYX)

NYSE Euronext, through its subsidiaries, operates securities exchanges. It operates various stock exchanges, including the New York Stock Exchange (NYSE), NYSE Arca, Inc., and NYSE Amex LLC in the United States; and five European-based exchanges that comprise Euronext N.V. ? the Paris, Amsterdam, Brussels, and Lisbon stock exchanges, as well as the NYSE Liffe derivatives markets in London, Paris, Amsterdam, Brussels, and Lisbon. The company?s Derivatives segment provides access to trade execution in derivatives products, options, and futures; offers clearing services for derivative products; and sells and distributes market data and related information. NYSE Euronext?s Cash Trading and Listings segment engages in offering access to trade execution in cash trading and settlement of transactions in European markets; obtaining new listings and servicing existing listings; selling and distributing market data and related information; and providing regulatory services. Its Info rmation Services and Technology Solutions segment operates sell side and buy side connectivity networks for its markets and for other market centers, and market participants in the United States, Europe, and Asia; provides trading and information technology software and solutions; sells and distributes market data and related information to data subscribers for proprietary data products; and offers asset management services, and consultancy services to exchanges and liquidity centers. The company is headquartered in New York, New York.

Advisors’ Opinion:

  • [By Anna Prior]

    IntercontinentalExchange Inc.(ICE) and NYSE Euronext sa(NYX)id Friday they had received the necessary regulatory approvals to close their deal. ICE’s $9.4 billion acquisition of NYSE will close Wednesday, the companies said.

  • [By Jason Cunningham]

    NYSE Euronext (NYSE: NYX) CEO and director Duncan Niederauer appeared on CNBC Tuesday to discuss his excitement over Twitter’s (NYSE: TWTR) highly anticipated IPO on Thursday.